Polymeric precipitation inhibitor differently affects cocrystal surface and bulk solution phase transformations

被引:8
作者
Shigemura, Marii [1 ]
Omori, Maaya [1 ]
Sugano, Kiyohiko [1 ]
机构
[1] Ritsumeikan Univ, Coll Pharmaceut Sci, Mol Pharmaceut Lab, 1-1-1 Noji Higashi, Kusatsu, Shiga 5258577, Japan
关键词
Cocrystal; Dissolution; Non-sink; Supersaturation; Polymer; Carbamazepine; Surface; PHARMACEUTICAL COCRYSTAL; DISSOLUTION PROFILE; DIFFUSION LAYER; CARBAMAZEPINE; SOLUBILITY; CRYSTAL; SUPERSATURATION; SOLVENT; WATER; CRYSTALLIZATION;
D O I
10.1016/j.jddst.2021.103029
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
During the dissolution of cocrystal particles, solution-mediated phase transformation (SMPT) can occur either on the particle surface (PS-SMPT) or in the bulk phase solution (BP-SMPT). In this study, we compared the effect of various polymers on PS-SMPT and BP-SMPT for the first time using carbamazepine saccharine cocrystal (CBZSAC) as a model drug. Polyethylene glycol 6000 (PEG), polyvinylpyrrolidone K-30 (PVP), hydroxypropyl methylcellulose (HPMC), hydroxypropyl methylcellulose acetate succinate (HPMC-AS), amino methacrylate copolymer (EPO), and methacrylic acid copolymers (L100-55) were used as polymeric precipitation inhibitors. In the non-sink dissolution test, CBZ-SAC rapidly transforms to CBZ dihydrate (CBZ DH) via PS-SMPT in the absence of polymers. The polymers enhanced the dissolution rate and subsequent supersaturated CBZ concentration in the order of HPMC-AS > HPMC > EPO >> PVP approximate to L100-55 approximate to PEG. On the other hand, in the solvent-shift precipitation test, these polymers inhibited the precipitation of CBZ DH in a different order (EPO > HPMC > HPMCAS >> L100-55 approximate to PVP >> PEG). The polymers affected the crystal habit of CBZ DH differently between PS-SMPT and BP-SMPT. Direct PS-SMPT observation by real-time polarized light microscopy (RT-PLM) showed that PSSMPT was significantly inhibited by HPMC-AS, HPMC, and EPO, but less by PVP, L100-55, and PEG. Differences in solid surface pH and heterogeneous nucleation were discussed as the reason for the difference in the inhibitory effect between polymers in PS-SMPT and BP-SMPT. In conclusion, the inhibitory effect of polymers can differ between PS-SMPT and BP-SMPT. For the successful development of a cocrystal formulation, it is important to select a potent inhibitor of PS-SMPT.
引用
收藏
页数:8
相关论文
共 60 条
[11]   Improving the Solubility and Bioavailability of Apixaban via Apixaban-Oxalic Acid Cocrystal [J].
Chen, Yong ;
Li, Long ;
Yao, Jia ;
Ma, Yu-Yu ;
Chen, Jia-Mei ;
Lu, Tong-Bu .
CRYSTAL GROWTH & DESIGN, 2016, 16 (05) :2923-2930
[12]   Formulation of a Danazol Cocrystal with Controlled Supersaturation Plays an Essential Role in Improving Bioavailability [J].
Childs, Scott L. ;
Kandi, Praveen ;
Lingireddy, Sreenivas Reddy .
MOLECULAR PHARMACEUTICS, 2013, 10 (08) :3112-3127
[13]   Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs [J].
Galia, E ;
Nicolaides, E ;
Hörter, D ;
Löbenberg, R ;
Reppas, C ;
Dressman, JB .
PHARMACEUTICAL RESEARCH, 1998, 15 (05) :698-705
[14]   Solubility Advantage of Pharmaceutical Cocrystals [J].
Good, David J. ;
Rodriguez-Hornedo, Nair .
CRYSTAL GROWTH & DESIGN, 2009, 9 (05) :2252-2264
[15]   Solution-mediated phase transformation: Significance during dissolution and implications for bioavailability [J].
Greco, Kristyn ;
Bogner, Robin .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2012, 101 (09) :2996-3018
[16]   Gastric Emptying and Small Bowel Water Content after Administration of Grapefruit Juice Compared to Water and Isocaloric Solutions of Glucose and Fructose: A Four-Way Crossover MRI Pilot Study in Healthy Subjects [J].
Grimm, Michael ;
Koziolek, Mirko ;
Saleh, Marwa ;
Schneider, Felix ;
Garbacz, Grzegorz ;
Kuehn, Jens-Peter ;
Weitschies, Werner .
MOLECULAR PHARMACEUTICS, 2018, 15 (02) :548-559
[17]   Insight into Flufenamic Acid Cocrystal Dissolution in the Presence of a Polymer in Solution: from Single Crystal to Powder Dissolution [J].
Guo, Minshan ;
Wang, Ke ;
Qiao, Ning ;
Fabian, Laszlo ;
Sadiq, Ghazala ;
Li, Mingzhong .
MOLECULAR PHARMACEUTICS, 2017, 14 (12) :4583-4596
[18]   Modifying the Diffusion Layer of Soluble Salts of Poorly Soluble Basic Drugs To Improve Dissolution Performance [J].
Hawley, Michael ;
Morozowich, Walter .
MOLECULAR PHARMACEUTICS, 2010, 7 (05) :1441-1449
[19]   Performance comparison of a co-crystal of carbamazepine with marketed product [J].
Hickey, Magali B. ;
Peterson, Matthew L. ;
Scoppettuolo, Lisa A. ;
Morrisette, Sherry L. ;
Vetter, Anna ;
Guzman, Hector ;
Remenar, Julius F. ;
Zhang, Zhong ;
Tawa, Mark D. ;
Haley, Sean ;
Zaworotko, Michael J. ;
Almarsson, Orn .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2007, 67 (01) :112-119
[20]   Cocrystal Solubility Advantage Diagrams as a Means to Control Dissolution, Supersaturation, and Precipitation [J].
Huang, Yaohui ;
Kuminek, Gislaine ;
Roy, Lilly ;
Cavanagh, Katie L. ;
Yin, Quxiang ;
Rodriguez-Hornedo, Nair .
MOLECULAR PHARMACEUTICS, 2019, 16 (09) :3887-3895